Despite the ASCENT-07 trial failing its primary progression-free survival (PFS) endpoint, an early overall survival (OS) signal emerged. This divergence suggests the drug may confer a survival advantage not captured by the initial endpoint, complicating the definition of a "negative" trial and warranting further follow-up.

The trial's active monitoring arm had a 96% overall survival rate at 3 years. This high baseline survival, due to effective subsequent treatments for relapsed patients, makes it statistically challenging to demonstrate an OS benefit for any adjuvant therapy. This highlights a growing challenge for adjuvant trial design in cancers with effective salvage options.

In pivotal ADC trials like ASCENT-03 and 04, over 80% of patients in the control (chemotherapy) arm received the ADC upon progression. This high crossover rate makes interpreting overall survival (OS) data difficult, as the control group's outcomes are artificially improved by subsequent access to the novel drug.

The control arm in the EMBARK study was blinded to PSA results, preventing physicians from intervening with standard-of-care AR antagonists at PSA progression. This design likely delayed subsequent effective therapies, making the control arm underperform and potentially exaggerating the overall survival benefit of the experimental arms.

An overall survival (OS) benefit in an adjuvant trial may not be meaningful for patients in systems (e.g., the U.S.) with guaranteed access to the same effective immunotherapy upon recurrence. The crucial, unanswered question is whether treating micrometastatic disease is inherently superior to treating macroscopic disease later, a distinction current trial data doesn't clarify.

The PEACE-3 steering committee felt its initial positive OS signal was unreliable due to non-proportional curves, despite meeting the statistical goal. This suggests a high level of self-imposed rigor, as early curve crossing can be due to statistical chance when event numbers are low, rather than a true lack of benefit.

In the CREST trial, the FDA's critique heavily emphasized an overall survival hazard ratio above one. Though statistically insignificant and based on immature data, this single figure created a powerful suggestion of potential harm that overshadowed the positive primary endpoint and likely contributed to the panel's divided vote.

Unlike a competing trial's marginal benefit (HR 0.8) for non-BRCA HRR patients, TALAPRO-3 demonstrated a clinically meaningful hazard ratio of 0.56. This superior performance could lead clinicians to strongly favor the talazoparib combination for this specific and often debated patient population.

The BREAKAWAY trial's OS data is from a small, crossover-allowed study, making it hard to interpret alone. However, its findings are believable because they align with and reinforce a "building body of evidence" from larger trials like PROPEL and TALA PRO 2, which also show a survival benefit for PARP inhibitor combinations.